Valuation : Bicara Therapeutics Inc.

Market Cap 1.53B 1.32B 1.24B 1.13B 2.12B 145B 2.13B 14.67B 5.69B 74.27B 5.76B 5.63B 239B P/E 2026 *
-6.76x
P/E 2027 * -6.51x
Enterprise Value 1.22B 1.05B 986M 901M 1.69B 115B 1.69B 11.66B 4.52B 59.02B 4.57B 4.48B 190B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.73%
1 week-1.11%
Current month+0.22%
1 month-10.51%
3 months+15.85%
6 months+25.24%
Current year+37.67%
1 week 22.61
Extreme 22.61
24.35
1 month 22.61
Extreme 22.61
28.43
Current year 13.75
Extreme 13.75
30.99
1 year 10.3
Extreme 10.295
30.99
3 years 7.8
Extreme 7.8
30.99
5 years 7.8
Extreme 7.8
30.99
10 years 7.8
Extreme 7.8
30.99
Manager TitleAgeSince
Chief Executive Officer 36 2019-12-31
President 49 2020-09-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 36 2019-12-31
Director/Board Member 50 2023-09-20
Director/Board Member 46 2023-09-20
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Free

Chief Financial Officer

285,000 0.4307%
8/10/26 Exercice

Chief Financial Officer

37,500 0.0567%
8/10/26 Exercice

Chairperson

56,250 0.0850%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%-1.11%+92.12% - 1.53B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.31%+0.12%+47.64%+177.58% 28.06B
Weighted average by Cap. -1.52%+0.17%+38.67%+137.35%

Financials

2026 *2027 *
Net sales - -
Net income -226M -195M -183M -167M -313M -21.35B -314M -2.16B -840M -10.96B -849M -831M -35.29B -256M -220M -207M -189M -354M -24.18B -355M -2.45B -951M -12.41B -962M -941M -39.97B
Net Debt -315M -271M -255M -233M -436M -29.73B -437M -3.01B -1.17B -15.25B -1.18B -1.16B -49.14B -405M -349M -328M -300M -561M -38.27B -562M -3.88B -1.5B -19.64B -1.52B -1.49B -63.26B
Logo Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Employees
103
Date Price Change Volume
26-09-04 US$23.17 -0.73% 296,877
26-09-03 US$23.34 -0.93% 259,736
26-09-02 US$23.56 +0.60% 518,793
26-09-01 US$23.42 +1.30% 429,859
26-08-31 US$23.12 -1.32% 511,965
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
23.17USD
Average target price
34.54USD
Spread / Average Target
+49.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCAX Stock